Main outcome measures: Demographic and clinical characteristics of patients who attended the service; correlates of selection for antiviral treatment; and clinical and virological outcomes of treatment.
Results: Of the 1043 inmates who attended the clinics, 851 were men (82%) and 994 (95%) were referred for HCV infection; the mean age for this group was 33 years (range, 18–74 years). In the case–control series (185 treated and 186 untreated patients), selection for treatment was not biased by culturally and linguistically diverse background, current methadone treatment or psychiatric status. In the treated group, 76 of 138 genotyped patients had a genotype that is predictive of favourable treatment response, and a small minority of those with available liver biopsy results had established cirrhosis (7/119 patients). Of treated patients for whom complete follow-up data were available, 55% achieved sustained virological response and 100% adhered to therapy. In addition, treatment episodes were not especially complicated.
- 1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29.
- 2. Razali K, Thein HH, Bell J, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007; 91: 228-235.
- 3. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
- 4. Shiell A. Economic analyses for hepatitis C: a review of Australia’s response. Canberra: Department of Health and Aged Care, 1998.
- 5. Mison LM, Young IF, O’Donoghue M, et al. Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population. Transfusion 1997; 37: 73-78.
- 6. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005; 20: 1082-1086.
- 7. Butler T, Milne L. The 2001 New South Wales Inmate Health Survey. Sydney: Corrections Health Service, 2003. http://www.justicehealth.nsw.gov.au/publications/Inmate_Health_Survey_2001.pdf (accessed Mar 2010).
- 8. Butler T, Boonwaat L, Hailstone S, et al. The 2004 Australian prison entrants’ blood-borne virus and risk behaviour survey. Aust N Z J Public Health 2007; 31: 44-50.
- 9. Post JJ, Dolan KA, Whybin LR, et al. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Med J Aust 2001; 174: 183-184. <MJA full text>
- 10. Haber PS, Parsons SJ, Harper SE, et al. Transmission of hepatitis C within Australian prisons. Med J Aust 1999; 171: 31-33. <MJA full text>
- 11. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451.
- 12. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-672.
- 13. Justice Health. Justice Health Annual Report 2005–2006. Sydney: Justice Health, 2006. http://www.justicehealth.nsw.gov.au/publications/jh_ar_05-06.pdf (accessed Mar 2010).
- 14. Farley J, Wong VK, Chung HV, et al. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Can J Gastroenterol 2005; 19: 153-156.
- 15. Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138: 187-190.
- 16. Skipper C, Guy JM, Parkes J, et al. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003; 52: 1500-1504.
- 17. Spaulding AC, Weinbaum CM, Lau DTY, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006; 144: 762-769.
- 18. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med 2001; 47: 45-50.
- 19. Farley J, Vasdev S, Fischer B, et al. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005; 95: 1737-1739.
- 20. Batey R, Jones T, McCallister C. Prisons and HCV: a review and a report on an experience in New South Wales, Australia. Int J Prison Health 2008; 4: 156-163.
- 21. Australian Government Department of Health and Ageing. National hepatitis C strategy 2005–2008. Canberra: Commonwealth of Australia, 2005.
- 22. NSW Department of Health. NSW hepatitis C strategy 2007–2009. Sydney: NSW Department of Health, 2007.
- 23. Hepatitis C Subcommittee, Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis. Hepatitis C prevention, treatment and care: guidelines for Australian custodial settings. Canberra: Australian Government Department of Health and Ageing, 2008.
- 24. Boutwell AE, Allen SA, Rich JD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005; 40 Suppl 5: S367-S372.
- 25. NSW Department of Correctives Services. Statistical report 2006/07. http://www.dcs.nsw.gov.au/information/research_and_statistics/other_reports/or008.pdf (accessed Mar 2010).
- 26. Sylvestre D. Hepatitis C treatment in drug users: perception versus evidence. Eur J Gastroenterol Hepatol 2006; 18: 129-130.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.